Erratum: Cytomegalovirus prophylaxis in high-risk kidney transplant recipients (American Journal of Transplantation (2010) 10 (1228-1237) DOI: 10.1111/j.1600-6143.2010.03074.x);The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

American Journal of Transplantation

Volumn 10, Issue 5, 2010, Pages 1228-1237

  Humar, A ^a   Lebranchu, Y ^b   Vincenti, F ^c   Blumberg, E A ^d   Punch, J D ^e   Limaye, A P ^f   Abramowicz, D ^g   Jardine, A G ^h   Voulgari, A T ⁱ   Ives, J ⁱ   Hauser, I A ^j   Peeters, P ^k  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITÉ DE TOURS   (France)

^c UCSF Medical Center at Parnassus   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g ERASME HOSPITAL   (Belgium)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ ROCHE PRODUCTS LTD   (United Kingdom)

^j GOETHE UNIVERSITY   (Germany)

^k GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Antivirals; Cytomegalovirus (CMV); Prophylaxis; Valganciclovir

Indexed keywords

GANCICLOVIR; PLACEBO; VALGANCICLOVIR;

ADULT; AGRANULOCYTOSIS; ANEMIA; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPERKALEMIA; HYPERTENSION; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LABORATORY TEST; LEUKOPENIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 77950468641     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03214.x     Document Type: Erratum

References (25)

1. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004 4 : 928 936. (Pubitemid 38745592)
2. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005 5 : 218 227. (Pubitemid 40179508)
3. Paya CV, Razonable RR. Cytomegalovirus infection after organ transplantation. In : Bowden RA, Ljungman P, Paya CV, eds. Transplant Infections, 2nd Ed.
4. Rubin RH. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: The end of the 'silo hypothesis'. Curr Opin Infect Dis 2007 20 : 399 407.
5. Kranz B, Vester U, Wingen A-M et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant 2008 12 : 474 478. (Pubitemid 351652068)
6. Hjelmesaeth J, Muller F, Jenssen T, Rollag H, Sagedal S, Hartmann A. Is there a link between cytomegalovirus infection and new-onset post transplantation diabetes mellitus?Potential mechanisms of virus induced beta-cell damage. Nephrol Dial Transplant 2005 20 : 2311 2315. (Pubitemid 41548852)
7. Cytomegalovirus. Am J Transplant 2004 4 (Suppl 10 51 58.
8. Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomised controlled trials. Lancet 2005 365 : 2105 2115.
9. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005 143 : 870 880. (Pubitemid 46202222)
10. Lowance D, Neumayer HH, Legendre CM et al. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999 340 : 1462 1470. (Pubitemid 29220545)
11. Limaye AP, Bakthavatsalam R, Kim HW et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004 78 : 1390 1396. (Pubitemid 39507981)
12. Doyle AM, Warburton KM, Goral S, Blumberg E, Grossman RA, Bloom RD. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006 81 : 1106 1111. (Pubitemid 43754659)
13. Zamora MR, Nicolls MR, Hodges TN et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004 4 : 1635 1642.
14. Valentine VG, Weill D, Lombard GA et al. Ganciclovir for cytomegalovirus: A call for indefinite prophylaxis. Am J Transplant 2007 7 (S2) : 505.
15. Valentine VG, Weill D, Gupta MR et al. Ganciclovir for cytomegalovirus: A call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 2008 27 : 875 881.
16. Schnitzler MA, Lowell JA, Hmiel SP et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: The importance of HLA-DR matching. J Am Soc Nephrol 2003 14 : 780 785.
17. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006 6 : 262 274. (Pubitemid 43382161)
18. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000 356 : 645 649. (Pubitemid 30627592)
19. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004 4 : 611 620. (Pubitemid 38523584)
20. Khoury JA, Storch GA, Bohl DL et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006 6 : 2134 2143.
21. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: Advantages of preemptive therapy. Rev Med Virol 2006 16 : 281 287. (Pubitemid 44497309)
22. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008 8 : 975 983. (Pubitemid 351537752)
23. Solidoro P, Libertucci D, Delsedime L et al. Combined cytomegalovirus prophylaxis in lung transplantation: Effects on acute rejection, lymphocytic bronchitis/bronchiolitis, and herpes virus infections. Transplant Proc 2008 40 : 2013 2014.
24. Luan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009 20 : 2449 2458.
25. Pouteil-Noble C, Ecochard R, Betuel H, Dubernard JM, Aymard M, Touraine JL. HLA B and DR mismatching, a risk factor for cytomegalovirus infection after renal transplantation. Clin Transplantation 1993 7 : 467 474. (Pubitemid 23293293)